Phosphatidylinositol 4,5-bisphosphate optical uncaging potentiates exocytosis

  1. Alexander M Walter  Is a corresponding author
  2. Rainer Müller
  3. Bassam Tawfik
  4. Keimpe DB Wierda
  5. Paulo S Pinheiro
  6. André Nadler
  7. Anthony W McCarthy
  8. Iwona Ziomkiewicz
  9. Martin Kruse
  10. Gregor Reither
  11. Jens Rettig
  12. Martin Lehmann
  13. Volker Haucke
  14. Bertil Hille
  15. Carsten Schultz
  16. Jakob Balslev Sorensen  Is a corresponding author
  1. University of Copenhagen, Denmark
  2. European Molecular Biology Laboratory (EMBL), Germany
  3. Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Germany
  4. University of Washington School of Medicine, United States
  5. Saarland University, Germany

Abstract

Phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] is essential for exocytosis. Classical ways of manipulating PI(4,5)P2 levels are slower than metabolism, making it difficult to distinguish effects of PI(4,5)P2 from those of its metabolites. We developed a membrane-permeant, photoactivatable PI(4,5)P2, which is loaded into cells in an inactive form and activated by light, allowing sub-second increases in PI(4,5)P2 levels. By combining this compound with electrophysiological measurements in mouse adrenal chromaffin cells, we show that PI(4,5)P2 uncaging potentiates exocytosis and identify synaptotagmin-1 (the Ca2+ sensor for exocytosis) and Munc13-2 (a vesicle priming protein) as the relevant effector proteins. PI(4,5)P2 activation of exocytosis did not depend on the PI(4,5)P2-binding CAPS-proteins, suggesting that PI(4,5)P2 uncaging bypasses CAPS-function. Finally, PI(4,5)P2 uncaging triggered the rapid fusion of a subset of readily-releasable vesicles, revealing a rapid role of PI(4,5)P2 in fusion triggering. Thus, optical uncaging of signaling lipids can uncover their rapid effects on cellular processes and identify lipid effectors.

Article and author information

Author details

  1. Alexander M Walter

    Center for Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    For correspondence
    awalter@fmp-berlin.de
    Competing interests
    No competing interests declared.
  2. Rainer Müller

    Cell Biology and Biophysics Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3464-494X
  3. Bassam Tawfik

    Center for Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1193-8494
  4. Keimpe DB Wierda

    Center for Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8784-9490
  5. Paulo S Pinheiro

    Center for Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  6. André Nadler

    Cell Biology and Biophysics Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
    Competing interests
    No competing interests declared.
  7. Anthony W McCarthy

    Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany
    Competing interests
    No competing interests declared.
  8. Iwona Ziomkiewicz

    Center for Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    Iwona Ziomkiewicz, Performed experiments as an employee of University of Copenhagen and is now an employee of AstraZeneca; IZ has no financial investments in AstraZeneca.
  9. Martin Kruse

    Department of Physiology and Biophysics, University of Washington School of Medicine, Seattle, United States
    Competing interests
    No competing interests declared.
  10. Gregor Reither

    Cell Biology and Biophysics Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
    Competing interests
    No competing interests declared.
  11. Jens Rettig

    Center for Integrative Physiology and Molecular Medicine, Saarland University, Homburg, Germany
    Competing interests
    No competing interests declared.
  12. Martin Lehmann

    Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany
    Competing interests
    No competing interests declared.
  13. Volker Haucke

    Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany
    Competing interests
    No competing interests declared.
  14. Bertil Hille

    Department of Physiology and Biophysics, University of Washington School of Medicine, Seattle, United States
    Competing interests
    No competing interests declared.
  15. Carsten Schultz

    Cell Biology and Biophysics Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
    Competing interests
    No competing interests declared.
  16. Jakob Balslev Sorensen

    Center for Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
    For correspondence
    jakobbs@sund.ku.dk
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5465-3769

Funding

European Union 7th Framework programme (HEALTH-F2-2009-242167)

  • Jakob Balslev Sorensen

The independent Research Fond Denmark

  • Jakob Balslev Sorensen

The Novo Nordisk Foundation

  • Jakob Balslev Sorensen

The Lundbeck Foundation

  • Paulo S Pinheiro
  • Jakob Balslev Sorensen

European Molecular Biology Laboratory

  • Carsten Schultz

Deutsche Forschungsgemeinschaft (Transregio83)

  • Alexander M Walter
  • Carsten Schultz

Deutsche Forschungsgemeinschaft (Emmy Noether Programme)

  • Alexander M Walter

National Institutes of Health (R37NS008174)

  • Bertil Hille

Alexander von Humboldt-Stiftung

  • Martin Kruse

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Permission to keep and breed knockout mice for this study was obtained from The Danish Animal Experiments Inspectorate (2006/562−43, 2012−15−2935−00001). The animals were maintained in an AAALAC-accredited stable in accordance with institutional guidelines as overseen by the Institutional Animal Care and Use Committee (IACUC).

Copyright

© 2017, Walter et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,762
    views
  • 838
    downloads
  • 42
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Alexander M Walter
  2. Rainer Müller
  3. Bassam Tawfik
  4. Keimpe DB Wierda
  5. Paulo S Pinheiro
  6. André Nadler
  7. Anthony W McCarthy
  8. Iwona Ziomkiewicz
  9. Martin Kruse
  10. Gregor Reither
  11. Jens Rettig
  12. Martin Lehmann
  13. Volker Haucke
  14. Bertil Hille
  15. Carsten Schultz
  16. Jakob Balslev Sorensen
(2017)
Phosphatidylinositol 4,5-bisphosphate optical uncaging potentiates exocytosis
eLife 6:e30203.
https://doi.org/10.7554/eLife.30203

Share this article

https://doi.org/10.7554/eLife.30203

Further reading

    1. Cell Biology
    2. Stem Cells and Regenerative Medicine
    Nathaniel Paul Meyer, Tania Singh ... Diane L Barber
    Research Article

    Our understanding of the transitions of human embryonic stem cells between distinct stages of pluripotency relies predominantly on regulation by transcriptional and epigenetic programs with limited insight on the role of established morphological changes. We report remodeling of the actin cytoskeleton of human embryonic stem cells (hESCs) as they transition from primed to naïve pluripotency which includes assembly of a ring of contractile actin filaments encapsulating colonies of naïve hESCs. Activity of the Arp2/3 complex is required for the actin ring, to establish uniform cell mechanics within naïve colonies, promote nuclear translocation of the Hippo pathway effectors YAP and TAZ, and effective transition to naïve pluripotency. RNA-sequencing analysis confirms that Arp2/3 complex activity regulates Hippo signaling in hESCs, and impaired naïve pluripotency with inhibited Arp2/3 complex activity is rescued by expressing a constitutively active, nuclear-localized YAP-S127A. Moreover, expression of YAP-S127A partially restores the actin filament fence with Arp2/3 complex inhibition, suggesting that actin filament remodeling is both upstream and downstream of YAP activity. These new findings on the cell biology of hESCs reveal a mechanism for cytoskeletal dynamics coordinating cell mechanics to regulate gene expression and facilitate transitions between pluripotency states.

    1. Cell Biology
    Xiaojiao Hua, Chen Zhao ... Yan Zhou
    Research Article

    The β-catenin-dependent canonical Wnt signaling is pivotal in organ development, tissue homeostasis, and cancer. Here, we identified an upstream enhancer of Ctnnb1 – the coding gene for β-catenin, named ieCtnnb1 (intestinal enhancer of Ctnnb1), which is crucial for intestinal homeostasis. ieCtnnb1 is predominantly active in the base of small intestinal crypts and throughout the epithelia of large intestine. Knockout of ieCtnnb1 led to a reduction in Ctnnb1 transcription, compromising the canonical Wnt signaling in intestinal crypts. Single-cell sequencing revealed that ieCtnnb1 knockout altered epithelial compositions and potentially compromised functions of small intestinal crypts. While deletion of ieCtnnb1 hampered epithelial turnovers in physiologic conditions, it prevented occurrence and progression of Wnt/β-catenin-driven colorectal cancers. Human ieCTNNB1 drove reporter gene expression in a pattern highly similar to mouse ieCtnnb1. ieCTNNB1 contains a single-nucleotide polymorphism associated with CTNNB1 expression levels in human gastrointestinal epithelia. The enhancer activity of ieCTNNB1 in colorectal cancer tissues was stronger than that in adjacent normal tissues. HNF4α and phosphorylated CREB1 were identified as key trans-factors binding to ieCTNNB1 and regulating CTNNB1 transcription. Together, these findings unveil an enhancer-dependent mechanism controlling the dosage of Wnt signaling and homeostasis in intestinal epithelia.